Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Nasopharyngeal carcinoma screening

Introduction

Overview

Overview

Screening for nasopharyngeal carcinoma only is done in endemic areas. Different methods, such as measurement the titre of different types of antibodies against EBV and plasma EBV DNA, and endoscopic examination of nasopharynx can be used for screening.

Screening

Screening

Screening for nasopharyngeal carcinoma only is done in endemic areas, the screening methods which can be used are:[1][2][3][4][5][6][7][8]

References

References

  1. ↑ Altun, M.; Fandi, A.; Dupuis, O.; Cvitkovic, E.; Krajina, Z.; Eschwege, F. (1995). “Undifferentiated nasopharyngeal cancer (UCNT): Current diagnostic and therapeutic aspects”. International Journal of Radiation Oncology*Biology*Physics. 32 (3): 859–877. doi:10.1016/0360-3016(95)00516-2. ISSN 0360-3016.
  2. ↑ Wang, W.-Y.; Twu, C.-W.; Chen, H.-H.; Jan, J.-S.; Jiang, R.-S.; Chao, J. Y.C.; Liang, K.-L.; Chen, K.-W.; Wu, C.-T.; Lin, J.-C. (2010). “Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma”. Clinical Cancer Research. 16 (3): 1016–1024. doi:10.1158/1078-0432.CCR-09-2796. ISSN 1078-0432.
  3. ↑ Y. Zeng, L. G. Zhang, Y. C. Wu, Y. S. Huang, N. Q. Huang, J. Y. Li, Y. B. Wang, M. K. Jiang, Z. Fang & N. N. Meng (1985). “Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China”. International journal of cancer. 36 (5): 545–547. PMID 4055129. Unknown parameter |month= ignored (help)
  4. ↑ Y. S. Zong, J. S. Sham, M. H. Ng, X. T. Ou, Y. Q. Guo, S. A. Zheng, J. S. Liang & H. Qiu (1992). “Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma”. Cancer. 69 (1): 3–7. PMID 1309307. Unknown parameter |month= ignored (help)
  5. ↑ Wei-min Cheng, Kwok Hung Chan, Hong-lin Chen, Rui-xian Luo, S. Park Ng, Winsie Luk, Bo-jian Zheng, Ming-fang Ji, Jin-sheng Liang, Jonathan S. T. Sham, De-Kun Wang, Yong-sheng Zong & Mun Hon Ng (2002). “Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum”. International journal of cancer. 97 (4): 489–492. PMID 11802211. Unknown parameter |month= ignored (help)
  6. ↑ Chien, Yin-Chu; Chen, Jen-Yang; Liu, Mei-Ying; Yang, Hwai-I; Hsu, Mow-Ming; Chen, Chien-Jen; Yang, Czau-Siung (2001). “Serologic Markers of Epstein–Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men”. New England Journal of Medicine. 345 (26): 1877–1882. doi:10.1056/NEJMoa011610. ISSN 0028-4793.
  7. ↑ Yu, K. J.; Hsu, W.-L.; Pfeiffer, R. M.; Chiang, C.-J.; Wang, C.-P.; Lou, P.-J.; Cheng, Y.-J.; Gravitt, P.; Diehl, S. R.; Goldstein, A. M.; Chen, C.-J.; Hildesheim, A. (2011). “Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families”. Clinical Cancer Research. 17 (7): 1906–1914. doi:10.1158/1078-0432.CCR-10-1681. ISSN 1078-0432.
  8. ↑ Leung, S.-f. (2004). “Improved Accuracy of Detection of Nasopharyngeal Carcinoma by Combined Application of Circulating Epstein-Barr Virus DNA and Anti-Epstein-Barr Viral Capsid Antigen IgA Antibody”. Clinical Chemistry. 50 (2): 339–345. doi:10.1373/clinchem.2003.022426. ISSN 0009-9147.


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]